Edition:
United Kingdom

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

5,585JPY
17 May 2019
Change (% chg)

¥124 (+2.27%)
Prev Close
¥5,461
Open
¥5,582
Day's High
¥5,598
Day's Low
¥5,480
Volume
1,422,800
Avg. Vol
2,042,180
52-wk High
¥5,820
52-wk Low
¥3,277

Latest Key Developments (Source: Significant Developments)

Daiichi Sankyo Provides Update On Ongoing FDA Review For Quizartinib For Treatment Of Patients With Relapsed/Refractory FLT3-ITD AML
Thursday, 4 Apr 2019 

April 4 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::DAIICHI SANKYO PROVIDES UPDATE ON ONGOING FDA REVIEW FOR QUIZARTINIB FOR TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY FLT3-ITD AML.DAIICHI SANKYO CO LTD - NEW PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE IS AUGUST 25, 2019..DAIICHI SANKYO - FDA EXTENDED ACTION DATE TO ALLOW TIME TO REVIEW ADDITIONAL DATA SUBMITTED BY DAIICHI SANKYO IN ASSOCIATION WITH AN FDA REQUEST..  Full Article

Daiichi Sankyo Co - FDA Grants Priority Review For Co's New Drug Application For CSF1R Inhibitor Pexidartinib
Tuesday, 5 Feb 2019 

Feb 5 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::FDA GRANTS PRIORITY REVIEW FOR DAIICHI SANKYO'S NEW DRUG APPLICATION FOR CSF1R INHIBITOR PEXIDARTINIB FOR TREATMENT OF PATIENTS WITH TGCT, A RARE, DEBILITATING TUMOR.DAIICHI SANKYO CO LTD - FDA HAS DESIGNATED AUGUST 3, 2019 AS PDUFA ACTION DATE FOR APPLICATION.  Full Article

Daiichi Sankyo To Sell Daiichi Sankyo Propharma Takatsuki Plant To Taiyo Holdings
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Japan's Daiichi Sankyo Co Ltd <4568.T>::ANNOUNCES TRANSFER OF DAIICHI SANKYO PROPHARMA TAKATSUKI PLANT AND COMPANY SPLIT.TO SELL TAKATSUKI PLANT TO TAIYO HOLDINGS <<<4626.T>>> FOR 37.6 BILLION YEN.  Full Article

Esperion Announces Agreement with Daiichi Sankyo Europe to Commercialize Bempedoic Acid in Europe
Friday, 4 Jan 2019 

Jan 4 (Reuters) - Esperion Therapeutics Inc ::ESPERION ANNOUNCES AGREEMENT WITH DAIICHI SANKYO EUROPE (DSE) TO COMMERCIALIZE BEMPEDOIC ACID IN EUROPE.ESPERION TO RECEIVE $300 MILLION IN UPFRONT AND NEAR-TERM MILESTONES.ESPERION TO RECEIVE $300 MILLION IN UPFRONT AND NEAR-TERM MILESTONES.TO RECEIVE UP TO $900 MILLION IN TOTAL MILESTONES.FDA AND EMA LDL-C APPROVAL DECISIONS ARE EXPECTED DURING FIRST HALF OF 2020.ESPERION THERAPEUTICS -GLOBAL CARDIOVASCULAR OUTCOMES TRIAL OF BEMPEDOIC ACID, IS ONGOING, CARDIOVASCULAR RISK REDUCTION RESULTS EXPECTED DURING 2022.WILL GRANT DAIICHI SANKYO EUROPE EXCLUSIVE COMMERCIALIZATION RIGHTS TO COMMERCIALIZE BEMPEDOIC ACID IN EUROPE.ESPERION WILL RECEIVE AN UPFRONT CASH PAYMENT OF $150 MILLION AS WELL AS $150 MILLION UPON FIRST COMMERCIAL SALES IN TERRITORY.DAIICHI SANKYO EUROPE WILL BE RESPONSIBLE FOR COMMERCIALIZATION IN TERRITORIES.WILL RECEIVE SUBSTANTIAL TIERED ROYALTIES ON NET TERRITORY SALES.ENTERED INTO A LICENSING AGREEMENT WITH DAIICHI SANKYO EUROPE (DSE).  Full Article

Medical Developments International Enters Distribution & License Deal With Daiichi Sankyo
Sunday, 7 Oct 2018 

Oct 8 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>::ENTERS DISTRIBUTION AND LICENSE AGREEMENT WITH DAIICHI SANKYO FOR PENTHROX IN CHINA, THAILAND & VIETNAM.DAIICHI SANKYO WILL PAY CO UP TO US$32.5 MILLION.MVP WILL FUND APPROVAL PROCESS UP TO US$10 MILLION & WILL OWN INTELLECTUAL PROPERTY GENERATED FROM PROGRAM.CO & DAIICHI SANKYO TO ENTER AGREEMENT WITH EPS INTERNATIONAL HOLDINGS TO GET PENTHROX APPROVED FOR SALE IN CHINA.  Full Article

Daiichi Sankyo to reorganize Kitasato Daiichi Sankyo Vaccine into specialized manufacturing unit
Friday, 27 Apr 2018 

April 27 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Says it plans to reorganize unit Kitasato Daiichi Sankyo Vaccine Co., Ltd. into a unit specializing in manufacturing, effective April 1, 2019.Says it will establish a Saitama-based wholly owned biotech unit in August.The manufacturing and production technology functions of Kitasato Daiichi Sankyo Vaccine will be transferred to the new unit on April 1, 2019 .The functions of Kitasato Daiichi Sankyo Vaccine other than manufacturing and production technologies (research and development, quality assurance, sales and etc.) and marketing approvals will be transferred to the co.Other details will be disclosed later.  Full Article

Vaxart Announces $5 Mln Inavir Revenue Milestone
Friday, 20 Apr 2018 

April 20 (Reuters) - Vaxart Inc ::VAXART ANNOUNCES $5 MILLION INAVIR® REVENUE MILESTONE.VAXART - NOTIFIED BY DAIICHI SANKYO CO THAT SALES OF INAVIR EXCEEDED ¥20 BILLION IN FISCAL YEAR 2017, TRIGGERING A $5 MILLION MILESTONE PAYMENT TO CO.VAXART INC - PAYMENT IS EXPECTED IN Q2 OF 2018.  Full Article

IM lowers conversion price of 2nd series convertible bonds to 3,070 won/share
Wednesday, 28 Mar 2018 

March 28 (Reuters) - IM Co Ltd <101390.KQ> ::* Says it lowered conversion price of 2nd series convertible bonds to 3,070 won/share from 3,215 won/share, effective March 28.  Full Article

Daiichi Sankyo completes share repurchase
Friday, 23 Mar 2018 

March 23 (Reuters) - Daiichi Sankyo Co Ltd <4568.T>:Says it accumulatively repurchased 15.7 million shares for 50 billion yen in total as of March 22.Share repurchase plan was disclosed on Oct. 31, 2017.  Full Article

Fortis Healthcare Gets Court Order Relating To Daiichi Sankyo Co Case
Thursday, 22 Mar 2018 

March 22 (Reuters) - Fortis Healthcare Ltd ::GETS COURT ORDER RELATING TO DAIICHI SANKYO COMPANY LIMITED CASE.COURT RESTRAINED RESPONDENTS/JUDGEMENT DEBTORS FROM TRANSFERRING SHARES/NCRP/ OPTIONALLY CONVERTIBLE DEBENTURES IN CO.CO ALSO PROHIBITED AND RESTRAINED FROM PERMITTING ANY SUCH TRANSFER OR MAKING SUCH PAYMENT.SAYS ‍COURT RESTRAINED RESPONDENTS/ JUDGEMENT DEBTORS FROM RECEIVING PAYMENT OF DIVIDENDS​.  Full Article

UPDATE 1-FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

May 14 Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.